MATEON THERAPEUTICS INC Contracts & Agreements

Binding Term Sheet dated April 26, 2024 (Filed With SEC on April 29, 2024)

Form of Subscription Agreement (Filed With SEC on July 13, 2023)

Form of Placement Agency Agreement, dated March 10, 2023 (Filed With SEC on July 13, 2023)

Form of Warrant (Filed With SEC on July 13, 2023)

Form of Note (Filed With SEC on July 13, 2023)

Registration Rights Agreement (Filed With SEC on July 13, 2023)

Securities Purchase Agreement (Filed With SEC on June 27, 2022)

Convertible Promissory Note (Filed With SEC on June 27, 2022)

Securities Purchase Agreement (Filed With SEC on June 3, 2022)

Convertible Promissory Note (Filed With SEC on June 3, 2022)

Independent consulting agreement between Oncotelic Therapeutics, Inc. and Fatih Uckun, MD, Ph.D. dated May 1, 2022 (Filed With SEC on May 6, 2022)

Independent consulting agreement between Oncotelic Therapeutics, Inc. and Seymour Fein, MD dated May 1, 2022 (Filed With SEC on May 6, 2022)

Joint Venture Agreement relating to GMP Biotechnology Limited between Dragon Overseas Capital Limited, Oncotelic Therapeutics, Inc. and GMP Biotechnology Limited dated March 31,... (Filed With SEC on April 6, 2022)

License Agreement between Oncotelic Therapeutics, Inc. and GMP Biotechnology Limited dated March 31, 2022 (Filed With SEC on April 6, 2022)

License Agreement between Oncotelic Therapeutics, Inc. and Sapu Holdings, LLC dated March 31, 2022 (Filed With SEC on April 6, 2022)

Form of Unsecured Convertible Note Purchase Agreement (Filed With SEC on February 2, 2022)

Form of Convertible Promissory Note (Filed With SEC on February 2, 2022)

Form of Securities Purchase Agreement (Filed With SEC on December 1, 2021)

Form of Convertible Promissory Note (Filed With SEC on December 1, 2021)

Finders Fee Agreement between Oncotelic Therapeutics, Inc. and JH Darbie & Co., Inc., dated October 26, 202 (Filed With SEC on December 1, 2021)

Unsecured Convertible Note Purchase Agreement between Oncotelic Therapeutics, Inc. and Golden Mountain Partners, LLC, dated October 25, etween Oncotelic Therapeutics, Inc. and... (Filed With SEC on October 28, 2021)

Promissory Note issued to Golden Mountain Partners, LLC, by Oncotelic Therapeutics, Inc., dated October 25, 2021 (Filed With SEC on October 28, 2021)

License Agreement between Oncotelic Therapeutics, Inc. and Autotelic, Inc., dated September 30, 2021 (Filed With SEC on October 4, 2021)

Unsecured Convertible Note Purchase Agreement between Oncotelic Therapeutics, Inc. and Golden Mountain Partners, LLC, dated September 21, 2021 (Filed With SEC on September 27, 2021)

Promissory Note issued to Golden Mountain Partners, LLC, by Oncotelic Therapeutics, Inc., dated September 21, 2021 (Filed With SEC on September 27, 2021)

Term Sheet between Oncotelic Therapeutics, Inc. and Autotelic, Inc., dated August 31, 2021 (Filed With SEC on September 3, 2021)

Form of Convertible Promissory Note, issued by the Company under the Note Purchase Agreement dated as of August 4, 2021 (Filed With SEC on August 5, 2021)

Form of Note Purchase Agreement, dated as of August 4, 2021, by and among the Company and the investors identified therein (Filed With SEC on August 5, 2021)

Form of Subscription Agreement, dated May 25, 2021 (Filed With SEC on June 1, 2021)

Form of Note, dated May 25, 2021 (Filed With SEC on June 1, 2021)

Equity Purchase Agreement by and between Oncotelic Therapeutics, Inc., and Peak One Opportunity Fund, L.P., dated May 3, 2021 (Filed With SEC on May 7, 2021)

Registration Rights Agreement, by and between Oncotelic Therapeutics, Inc., and Peak One Opportunity Fund, L.P., dated May 3, 2020 (Filed With SEC on May 7, 2021)

Form of Subscription Agreement (Filed With SEC on March 26, 2021)

Form of Edgepoint Warrant (Filed With SEC on March 26, 2021)

Form of Mateon Warrant (Filed With SEC on March 26, 2021)

Form of Note (Filed With SEC on March 26, 2021)

Form of Registration Rights Agreement (Filed With SEC on March 26, 2021)

Loan, Secured Convertible Note Purchase, and Security Agreement between the Company and Golden Mountain Partners, LLC dated June 27, 2020 (Filed With SEC on November 16, 2020)

Secured Convertible Promissory Note between the Company and Golden Mountain Partners, LLC dated June 27, 2020 (Filed With SEC on November 16, 2020)

License, Development and Commercialization Agreement between Mateon Therapeutics, Inc. and Windlas Biotech Private Limited dated November 10, 2020 (Filed With SEC on November 16, 2020)

Windlas Mateon MOU (Filed With SEC on September 28, 2020)

Form of Subscription Agreement, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Form of Placement Agency Agreement, dated February 25, 2020 (Filed With SEC on August 13, 2020)

Form of Edgepoint Warrant, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Form of Mateon Warrant, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Form of Note, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Form of Registration Rights Agreement, dated August 7, 2020 (Filed With SEC on August 13, 2020)

Expanded Access Program MSA (Filed With SEC on August 3, 2020)

Statement of Work (Filed With SEC on August 3, 2020)

Data Processing Agreement (Filed With SEC on August 3, 2020)

Form of Subscription Agreement, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Form of Placement Agency Agreement, dated February 25, 2020 (Filed With SEC on July 29, 2020)

Form of Edgepoint Warrant, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Form of Mateon Warrant, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Form of Note, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Registration Rights Agreement, dated July 23, 2020 (Filed With SEC on July 29, 2020)

Consulting Agreement by and between the Company and Artius, dated March 9, 2020 (Filed With SEC on June 22, 2020)

Consulting Agreement by and between the Company and Dr. Maida, dated May 5, 2020 (Filed With SEC on June 22, 2020)

NantCell Binding Termsheet (Filed With SEC on June 16, 2020)

AutotelicBIO Licensing Agreement (Filed With SEC on June 16, 2020)

Paycheck Protection Program Promissory Note dated April 21, 2020 between Mateon Therapeutics, Inc. and Silicon Valley Bank (Filed With SEC on April 27, 2020)

Research and Services Agreement (Filed With SEC on March 23, 2020)

Supplement Research and Services Agreement (Filed With SEC on March 23, 2020)

Employment Agreement dated August 23, 2019 between the Company and Dr. Fatih Uckun (Filed With SEC on November 25, 2019)

Form of Convertible Promissory Note, issued by the Company under the Note Purchase Agreement dated as of November 23, 2019 (Filed With SEC on November 25, 2019)

Form of Note Purchase Agreement, dated as of November 23, 2019, by and among the Company and the investors identified therein (Filed With SEC on November 25, 2019)

Amendment No. 1 to Agreement and Plan of Merger, dated as of November 1, 2019, by and among the Company, PointR Data, Inc. and Paris Acquisition Corp (Filed With SEC on November 12, 2019)

Investigational Product Supply and Use Authorization Agreement for OT-101 U.S. Expanded Access (IPSUA) dated September 5, 2019 between WideTrial and Oncotelic (Filed With SEC on September 10, 2019)

Agreement for Delivery and Licensed Use of Data Generated from OT-101 U.S. Expanded Access (Data License 1) dated September 5, 2019 between WideTrial and Oncotelic (Filed With SEC on September 10, 2019)

Agreement for Delivery and Licensed Use of WideTrial Bonus Dataset (Data License 2 Agreement) dated September 5, 2019 between WideTrial and Oncotelic (Filed With SEC on September 10, 2019)

Employment Agreement dated August 23, 2019 between the Company and Dr. Vuong Trieu (Filed With SEC on August 29, 2019)

Employment Agreement dated August 23, 2019 between the Company and Dr. Fatih Uckun (Filed With SEC on August 29, 2019)

Employment Agreement dated August 23, 2019 between the Company and Dr. Chulho Park (Filed With SEC on August 29, 2019)

Employment Agreement dated August 23, 2019 between the Company and Mr. Amit Shah (Filed With SEC on August 29, 2019)

Agreement and Plan of Merger, dated as of August 17, 2019, by and among the Company, PointR and Paris Acquisition Corporation (Filed With SEC on August 21, 2019)

Convertible Promissory Note between Mateon Therapeutics, Inc and PointR Data Inc. dated July 22nd, 2019 (Filed With SEC on July 24, 2019)

Note Purchase Agreement between Mateon Therapeutics, Inc and PointR Data Inc. dated July 22nd, 2019 (Filed With SEC on July 24, 2019)

Separation Agreement dated as of July 1, 2019 by and between the Company and Matthew M. Loar (Filed With SEC on July 5, 2019)

Amendment to Securities Purchase Agreement dated as of June 12, 2019 by and between the Company and Peak One Opportunity Fund, L.P (Filed With SEC on June 20, 2019)

Contingent Value Rights Agreement, dated April 17, 2019, by and among the Company, Oncotelic and American Stock Transfer and Trust Company LLC (Filed With SEC on April 25, 2019)

Agreement and Plan of Merger, dated as of April 17, 2019, by and among the Company, Oncotelic and Oncotelic Acquisition Corporation (Filed With SEC on April 18, 2019)

Form of Debenture, issued by the Company to PeakOne (Filed With SEC on April 18, 2019)

Form of Debenture, issued by the Company to the Bridge Investors (Filed With SEC on April 18, 2019)

Separation and Release Agreement, dated April 17, 2019, by and between the Company and William D. Schwieterman, M.D (Filed With SEC on April 18, 2019)

Form of Securities Purchase Agreement, dated as of April 17, 2019, by and among the Company and PeakOne (Filed With SEC on April 18, 2019)

Form of Securities Purchase Agreement, dated as of April 17, 2019, by and among the Company and the Bridge Investors (Filed With SEC on April 18, 2019)

Form of Placement Agent Purchase Warrant (Filed With SEC on June 13, 2018)

Form of Series A Warrant (Filed With SEC on April 16, 2018)

Form of Series B Warrant (Filed With SEC on April 16, 2018)

Form of Subscription Agreement (Filed With SEC on April 16, 2018)

Form of Registration Rights Agreement (Filed With SEC on April 16, 2018)

Engagement Letter, dated February 7, 2018, by and between the Registrant and Divine Capital Markets LLC (Filed With SEC on April 16, 2018)

Form of Securities Purchase Agreement (Filed With SEC on November 16, 2017)

Amendment No. 2 to Employment Agreement by and between the Registrant and William D. Schwieterman, dated as of October 2, 2017 (Filed With SEC on November 14, 2017)

Amendment No. 1 to Employment Agreement by and between the Registrant and Matthew M. Loar, dated as of October 2, 2017 (Filed With SEC on November 14, 2017)

Amendment No. 1 to Second Amended and Restated Employment Agreement by and between the Registrant and David J. Chaplin, dated as of October 2, 2017 (Filed With SEC on November 14, 2017)

PRE-FUNDED COMMON STOCK PURCHASE WARRANT MATEON THERAPEUTICS, INC. (Filed With SEC on June 13, 2017)

PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT MATEON THERAPEUTICS, INC. (Filed With SEC on June 13, 2017)

COMMON STOCK PURCHASE WARRANT MATEON THERAPEUTICS, INC. (Filed With SEC on June 13, 2017)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on June 13, 2017)

MATEON THERAPEUTICS, INC. 2017 EQUITY INCENTIVE PLAN (Filed With SEC on January 13, 2017)

MATEON THERAPEUTICS, INC. Stock Option Grant Notice Stock Option Grant under the Companys 2017 Equity Incentive Plan (Filed With SEC on January 13, 2017)

AMENDED AND RESTATED MATEON THERAPEUTICS, INC. 2005 STOCK PLAN (asamended and restated on January 12, 2017) (Filed With SEC on January 13, 2017)

AMENDED AND RESTATED MATEON THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN (as amended and restated on January 12, 2017) (Filed With SEC on January 13, 2017)

SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on October 28, 2016)

MATEON THERAPEUTICS, INC. AMENDED AND RESTATED DIRECTOR COMPENSATION POLICY AS IN EFFECT OCTOBER 25, 2016 (Filed With SEC on October 28, 2016)

MATEON THERAPEUTICS, INC. (Filed With SEC on August 2, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on August 6, 2015)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on August 6, 2015)

SEPARATION AGREEMENT AND RELEASE (Filed With SEC on August 6, 2015)

OXiGENE, INC. StockOption Grant Notice Stock Option Grant under the Companys 2015 Equity Incentive Plan (Filed With SEC on August 6, 2015)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (Filed With SEC on August 6, 2015)

COMMON STOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on March 20, 2015)

AMENDMENT NO. 9 TO STOCKHOLDER RIGHTS AGREEMENT (Filed With SEC on March 20, 2015)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 20, 2015)

EMPLOYMENT AGREEMENT AMENDMENT (Filed With SEC on November 13, 2014)

CONSULTING AGREEMENT (Filed With SEC on November 13, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on August 8, 2014)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (Filed With SEC on August 8, 2014)

SEPARATION AGREEMENT AND RELEASE (Filed With SEC on August 8, 2014)

OXiGENE, INC. AMENDEDAND RESTATED DIRECTOR COMPENSATION POLICY (Filed With SEC on August 8, 2014)

COMMON STOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on May 23, 2014)

AMENDMENT NO. 8 TO STOCKHOLDER RIGHTS AGREEMENT (Filed With SEC on May 23, 2014)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 23, 2014)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 23, 2014)

FOURTH AMENDMENT TO LEASE (Filed With SEC on May 8, 2014)

CONFIDENTIAL TREATMENT REQUESTED LICENSE AGREEMENT (Filed With SEC on March 20, 2014)

[Form of Warrant] COMMONSTOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on February 14, 2014)

[Form of Placement Agent Warrant] COMMON STOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on February 14, 2014)

FORM OF SECURITIES PURCHASE AGREEMENT (Filed With SEC on February 14, 2014)

[Form of Placement Agent Warrant] COMMON STOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on January 31, 2014)

[Form of Warrant] COMMONSTOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on January 31, 2014)

[Form of Placement Agent Warrant] COMMON STOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on January 24, 2014)

[Form of Warrant] COMMONSTOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on January 24, 2014)

FORM OF SECURITIES PURCHASE AGREEMENT (Filed With SEC on January 24, 2014)

430 ParkAvenue | New York, New York 10022 | 212 ###-###-#### | www.hcwco.com Member:FINRA/SIPC (Filed With SEC on September 20, 2013)

FORM OF COMMON STOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on September 20, 2013)

FORM OF AMENDMENT NO. 7 TO STOCKHOLDER RIGHTS AGREEMENT (Filed With SEC on September 20, 2013)

FORM OF SECURITIES PURCHASE AGREEMENT (Filed With SEC on September 20, 2013)

FORM OF REGISTRATION RIGHTS AGREEMENT (Filed With SEC on September 20, 2013)

[Form of Placement Agent Warrant] (Filed With SEC on August 29, 2013)

STOCK PURCHASE WARRANT TO SUBSCRIBE FOR AND PURCHASE COMMON STOCK OF OXiGENE, INC. (Filed With SEC on August 8, 2013)

THIRD AMENDMENT TO LEASE (Filed With SEC on May 9, 2013)

FORM OF SERIES [A/B] COMMON STOCK PURCHASE WARRANT OXIGENE, INC. (Filed With SEC on April 11, 2013)

FORM OF AMENDMENT NO. 6 TO STOCKHOLDER RIGHTS AGREEMENT (Filed With SEC on April 11, 2013)

FORM OF SECURITIES PURCHASE AGREEMENT (Filed With SEC on April 11, 2013)

FORM OF REGISTRATION RIGHTS AGREEMENT (Filed With SEC on April 11, 2013)

Exhibit B (Filed With SEC on March 15, 2013)

CONSULTING AGREEMENT (Filed With SEC on January 23, 2013)

FORM OF INDEMNIFICATIONAGREEMENT by and among THE PERSONS LISTED HEREIN and OXiGENE, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on August 13, 2012)

INDEMNIFICATION AGREEMENT by and among THE PERSONS LISTED HEREIN and OXiGENE, INC. Dated as of[ ], 2008 INDEMNIFICATION AGREEMENT (Filed With SEC on May 11, 2012)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 28, 2012)

AMENDMENT NO. 5 TO STOCKHOLDER RIGHTS AGREEMENT (Filed With SEC on November 28, 2011)

PURCHASE AGREEMENT (Filed With SEC on November 28, 2011)

WHEREAS: (Filed With SEC on November 28, 2011)

EX-101 INSTANCE DOCUMENT (Filed With SEC on November 10, 2011)

FORM OF SERIES E WARRANT (Filed With SEC on January 19, 2011)

FORMOF WARRANT EXCHANGE AGREEMENT (Filed With SEC on January 19, 2011)

FORMOF VOTING AGREEMENT (Filed With SEC on January 19, 2011)

AMENDMENT NO. 4 TO STOCKHOLDER RIGHTS AGREEMENT (Filed With SEC on January 19, 2011)

OXiGENE, Inc. (Filed With SEC on July 21, 2010)

FORM OF SERIES D WARRANT (Filed With SEC on March 26, 2010)

FORMOF AMENDMENT AND EXCHANGE AGREEMENT (Filed With SEC on March 26, 2010)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on March 11, 2010)

FORM OF SERIES A WARRANT (Filed With SEC on March 11, 2010)

FORM OF SERIES B WARRANT (Filed With SEC on March 11, 2010)

FORM OF SERIES C WARRANT (Filed With SEC on March 11, 2010)

FORM OF SERIES D WARRANT (Filed With SEC on March 11, 2010)

AMENDMENT NO. 3 TO STOCKHOLDER RIGHTS AGREEMENT (Filed With SEC on March 11, 2010)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 11, 2010)

VOTING AGREEMENT (Filed With SEC on March 11, 2010)

AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on February 12, 2010)

EX-2.1 Agreement and Plan of Merger by and among OXiGENE, Merger Sub, VaxGen and Stockholder Representative, dated October 14, 2009 (Filed With SEC on October 16, 2009)

Ex-1.1 Placement Agent Agreement dated as of July 15, 2009 (Filed With SEC on July 15, 2009)

Ex-4.1 Form of Five-Year Warrant issued to Investors (Filed With SEC on July 15, 2009)

Ex-4.2 Form of Short-Term Warrant issued to Investors (Filed With SEC on July 15, 2009)

Ex-10.1 Form of Subscription Agreement (Filed With SEC on July 15, 2009)

Ex-10.1 Amended and Restated Purchase Option Agreement (Filed With SEC on July 7, 2009)

Ex-10.2 Amended and Restated Registration Rights Agreement (Filed With SEC on July 7, 2009)

Ex-10.3 Termination Agreement (Filed With SEC on July 7, 2009)

Ex-10.1 Employment Agreement by and among OXiGENE and Dr. Peter Langecker, dated as of June 10, 2009 (Filed With SEC on June 17, 2009)

EX-10.1 SEPARATION AGREEMENT BETWEEN OXIGENE AND DR. WALICKE DATED AS OF JUNE 10, 2009 (Filed With SEC on June 12, 2009)

Ex-10.1 Office Lease Agreement, dated April 21, 2009 (Filed With SEC on May 15, 2009)

EX-10.51 409A AMENDMENT TO EMPLOYMENT AGREEMENT MR. CHAPLIN (Filed With SEC on March 30, 2009)

EX-10.52 409A AMENDMENT TO EMPLOYMENT AGREEMENT MR. KOLLINS (Filed With SEC on March 30, 2009)

EX-10.53 409A AMENDMENT TO EMPLOYMENT AGREEMENT MR. MURPHY (Filed With SEC on March 30, 2009)

EX-10.54 409A AMENDMENT TO EMPLOYMENT AGREEMENT DR. WALICKE (Filed With SEC on March 30, 2009)

EX-10.55 AMENDMENT NO 2 TO EMPLOYMENT AGREEMENT DR. CHAPLIN (Filed With SEC on March 30, 2009)

EX-10.56 AMENDMENT NO 2 TO EMPLOYMENT AGREEMENT MR. MURPHY (Filed With SEC on March 30, 2009)

EX-10.57 RESEARCH AND DEVELOPMENT AGREEMENT VIDA HOLDINGS (Filed With SEC on March 30, 2009)

EX-10.58 AMENDED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT VIDA HOLDINGS (Filed With SEC on March 30, 2009)

EX-10.59 LEASE (Filed With SEC on March 30, 2009)

EX-10.1 Amendment No. 1 to Employment Agreement (Filed With SEC on December 22, 2008)

EX-10.1 Form of Indemnification Agreement between OXiGENE and its Directors (Filed With SEC on October 24, 2008)

EX-10.2 OXiGENE, Inc. Amended and Restated Director Compensation Policy (Filed With SEC on October 24, 2008)

EX-10.3 Separation Agreement between OXiGENE and Dr. Chin dated October 22, 2008 (Filed With SEC on October 24, 2008)

EX-10.4 Amendment No. 3 Employment Agreement, dated October 22, 2008 (Filed With SEC on October 24, 2008)

Ex-4.1 Form of Direct Investment Warrant, to be dated as of October 17, 2008 (Filed With SEC on October 10, 2008)

Ex-10.1 Technology License Agreement dated as of October 1, 2008 (Filed With SEC on October 10, 2008)

Ex-10.2 Novated and Restated Technology License Agreement (Filed With SEC on October 10, 2008)

Ex-10.3 Stock and Warrant Purchase Agreement dated as of October 1, 2008 (Filed With SEC on October 10, 2008)

Ex-10.4 Purchase Option Agreement dated as of October 1, 2008 (Filed With SEC on October 10, 2008)

Ex-10.5 Registration Rights Agreement dated as of October 1, 2008 (Filed With SEC on October 10, 2008)

Ex-10.6 Additional Funding Agreement dated as of October 1, 2008 (Filed With SEC on October 10, 2008)

Ex-10.7 Amendment No. 1 to the Stockholder Rights Agreement (Filed With SEC on October 10, 2008)

Ex-4.1 Warrant for the purchase of shares of common stock, dated 2/19/2008 (Filed With SEC on February 21, 2008)

Ex-4.2 Registration Rights Agreement, dated 2/19/2008 (Filed With SEC on February 21, 2008)

Ex-10.1 Common Stock Purchase Agreement, dated 2/19/2008 (Filed With SEC on February 21, 2008)

EX-10.3 SEPARATION AGREEMENT BETWEEN THE COMPANY AND PETER HARRIS, M.D. DATED AUGUST 31, 2007 (Filed With SEC on November 9, 2007)

EMPLOYMENT AGREEMENT (Filed With SEC on August 1, 2007)

Ex-10.1 Amendment No. 2 to Employment Agreement, Mr. Citron dated July 9, 2007 (Filed With SEC on July 11, 2007)

Ex-10.1 Employment Agreement-John Kollins (Filed With SEC on May 7, 2007)

Ex-10.2 Amendment No. 1 to Employment Agreement-David Chaplin (Filed With SEC on May 7, 2007)

Ex-10.3 Separation Agreement-Scott Young (Filed With SEC on May 7, 2007)

Ex-10.1 Amendment No.1 to Employment Agreement - Mr. Citron (Filed With SEC on September 29, 2006)

EX-10.1 Dr. Chin Employment Agreement, dated 6/29/06 (Filed With SEC on July 6, 2006)

EX-10.2 Mr. Driscoll Separation Agreement, dated 6/29/06 (Filed With SEC on July 6, 2006)

EX-10.1 Dr. Harris Employment Agreement dated 4/25/06 (Filed With SEC on June 19, 2006)

Ex-10.35 Lease Modification Agreement No. 2 (Filed With SEC on May 3, 2006)

EX-10.29 Form of Incentive Stock Option Agreement (Filed With SEC on March 14, 2006)

EX-10.30 Form of Non-Qualified Stock Option Agreement (Filed With SEC on March 14, 2006)

EX-10.31 Form of Restricted Stock Agreement (Filed With SEC on March 14, 2006)

EX-1.1 UNDERWRITING AGREEMENT DATED AS OF DECEMBER 14, 2005 (Filed With SEC on December 15, 2005)

EX-10.1 Lease Modification Agreement No.1 (Filed With SEC on July 29, 2005)

EX-10.2 Description of Director Compensation Arrangements (Filed With SEC on July 29, 2005)

EX-10.3 Description of Named Executive Officer Compensation Arrangements (Filed With SEC on July 29, 2005)

EX-4.1 Stockholder Rights Agreement (Filed With SEC on March 30, 2005)

EX-10.41 DESCRIPTION OF DIRECTOR COMPENSATION (Filed With SEC on March 15, 2005)

EX-10.42 NAMED EXECUTIVE OFFICERS COMPENSATION ARRANGEMENTS (Filed With SEC on March 15, 2005)

3,336,117 Shares OXIGENE, INC. Common Stock (Filed With SEC on March 7, 2005)

LEASE BY AND BETWEEN THE REALTY ASSOCIATES FUND III AND (Filed With SEC on July 30, 2004)

SUBLEASE (Filed With SEC on July 30, 2004)

EMPLOYMENT AGREEMENT (Filed With SEC on May 5, 2004)

STOCK PLEDGE AND LOAN AGREEMENT (Filed With SEC on March 15, 2004)

OXIGENE, INC. (Filed With SEC on January 15, 2004)

Category

Industry

Companies

Contracts

MATEON THERAPEUTICS INC Contracts & Agreements